KR20210067483A - Cosmetic composition for enhancing skin barrier comprising basil oil - Google Patents
Cosmetic composition for enhancing skin barrier comprising basil oil Download PDFInfo
- Publication number
- KR20210067483A KR20210067483A KR1020190157149A KR20190157149A KR20210067483A KR 20210067483 A KR20210067483 A KR 20210067483A KR 1020190157149 A KR1020190157149 A KR 1020190157149A KR 20190157149 A KR20190157149 A KR 20190157149A KR 20210067483 A KR20210067483 A KR 20210067483A
- Authority
- KR
- South Korea
- Prior art keywords
- skin
- basil oil
- composition
- lotion
- cream
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 64
- 229940018006 basil oil Drugs 0.000 title claims abstract description 56
- 239000010619 basil oil Substances 0.000 title claims abstract description 56
- 230000008591 skin barrier function Effects 0.000 title claims abstract description 33
- 239000002537 cosmetic Substances 0.000 title claims abstract description 26
- 230000002708 enhancing effect Effects 0.000 title 1
- 210000002510 keratinocyte Anatomy 0.000 claims abstract description 29
- 230000014509 gene expression Effects 0.000 claims abstract description 24
- 238000005728 strengthening Methods 0.000 claims abstract description 14
- 230000037303 wrinkles Effects 0.000 claims abstract description 11
- 201000004624 Dermatitis Diseases 0.000 claims abstract description 5
- 230000036620 skin dryness Effects 0.000 claims abstract description 4
- 210000003491 skin Anatomy 0.000 claims description 26
- 230000036541 health Effects 0.000 claims description 22
- 235000013376 functional food Nutrition 0.000 claims description 19
- 239000006210 lotion Substances 0.000 claims description 18
- 230000004069 differentiation Effects 0.000 claims description 14
- 239000006071 cream Substances 0.000 claims description 11
- -1 pack Substances 0.000 claims description 11
- 102000034258 Envoplakin Human genes 0.000 claims description 9
- 108010011042 Envoplakin Proteins 0.000 claims description 9
- 230000001939 inductive effect Effects 0.000 claims description 6
- 108060008539 Transglutaminase Proteins 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 102000003601 transglutaminase Human genes 0.000 claims description 4
- 230000000475 sunscreen effect Effects 0.000 claims description 3
- 239000000516 sunscreening agent Substances 0.000 claims description 3
- 239000000686 essence Substances 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 239000008269 hand cream Substances 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000002453 shampoo Substances 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 230000001256 tonic effect Effects 0.000 claims description 2
- 244000223014 Syzygium aromaticum Species 0.000 claims 2
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 7
- 235000013305 food Nutrition 0.000 abstract description 7
- 230000009759 skin aging Effects 0.000 abstract description 7
- 210000004027 cell Anatomy 0.000 description 17
- 235000013402 health food Nutrition 0.000 description 11
- 238000009472 formulation Methods 0.000 description 10
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000013355 food flavoring agent Nutrition 0.000 description 7
- 210000004927 skin cell Anatomy 0.000 description 7
- 108010058721 transglutaminase 5 Proteins 0.000 description 7
- 108010016788 Cyclin-Dependent Kinase Inhibitor p21 Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 210000002615 epidermis Anatomy 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 210000000434 stratum corneum Anatomy 0.000 description 6
- LTHJXDSHSVNJKG-UHFFFAOYSA-N 2-[2-[2-[2-(2-methylprop-2-enoyloxy)ethoxy]ethoxy]ethoxy]ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCOCCOCCOCCOC(=O)C(C)=C LTHJXDSHSVNJKG-UHFFFAOYSA-N 0.000 description 5
- 102000000578 Cyclin-Dependent Kinase Inhibitor p21 Human genes 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 102100038098 Protein-glutamine gamma-glutamyltransferase 5 Human genes 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 4
- 102000009508 Cyclin-Dependent Kinase Inhibitor p16 Human genes 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 3
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 3
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 235000015203 fruit juice Nutrition 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101710179297 Cyclin-dependent kinase 1-A Proteins 0.000 description 2
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical class OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 101150094577 Evpl gene Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 240000004737 Ocimum americanum Species 0.000 description 2
- 235000004070 Ocimum canum Nutrition 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000809 air pollutant Substances 0.000 description 2
- 231100001243 air pollutant Toxicity 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000003780 keratinization Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 108700042657 p16 Genes Proteins 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000009993 protective function Effects 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 101100314273 Arabidopsis thaliana TOR1 gene Proteins 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 229940126074 CDK kinase inhibitor Drugs 0.000 description 1
- 101150113634 CDKN1A gene Proteins 0.000 description 1
- 101150041972 CDKN2A gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 description 1
- 101001069810 Homo sapiens Psoriasis susceptibility 1 candidate gene 2 protein Proteins 0.000 description 1
- 101100152841 Homo sapiens TGM5 gene Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100031784 Loricrin Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001529734 Ocimum Species 0.000 description 1
- 235000010676 Ocimum basilicum Nutrition 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 102100027184 Periplakin Human genes 0.000 description 1
- 101710202907 Periplakin Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 102100034249 Psoriasis susceptibility 1 candidate gene 2 protein Human genes 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 101150051212 TGM5 gene Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000001047 desmosome Anatomy 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 102000007236 involucrin Human genes 0.000 description 1
- 108010033564 involucrin Proteins 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 101150044508 key gene Proteins 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960000812 linaclotide Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 108010079309 loricrin Proteins 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 230000021616 negative regulation of cell division Effects 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Botany (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 바질 오일을 포함하는 피부장벽 강화용 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition for strengthening the skin barrier comprising basil oil.
피부는 외부로부터 개체를 보호하는 장벽기능이라는 매우 중요한 역할을 수행한다. 장벽기능은 외부로부터의 다양한 자극(화학물질, 대기오염물질, 건조한 환경, 자외선 등)에 대한 방어와 피부를 통한 체내 수분의 과도한 발산을 막는 보호 기능이며, 이러한 보호기능은 각질형성세포로 구성된 각질층이 정상적으로 형성되어 있을 경우에만 그 기능을 유지할 수 있다. The skin plays a very important role as a barrier function that protects the individual from the outside. The barrier function is a protective function that protects against various external stimuli (chemicals, air pollutants, dry environment, ultraviolet rays, etc.) and prevents excessive leakage of body moisture through the skin, and this protective function is the stratum corneum composed of keratinocytes. It can maintain its function only when it is normally formed.
표피 중에서도 가장 바깥쪽에 존재하는 각질층(Stratum corneum, horney layer)은 각질형성세포로부터 형성되며, 분화가 완결된 각질세포와 그를 둘러싼 지질층으로 구성되어 있다(Marcelo C. L. et al, J. Invest. Dermatol., 80, pp37-44, 1983). 각질세포는 표피 최하층에서 지속적으로 증식(proliferation)하는 기저세포(basal cell)가 단계적으로 형태 및 기능상의 변화를 거치며, 피부 표면까지 상승한 특징적인 세포이며, 일정 기간이 경과하면 오래된 각질세포는 피부에서 탈락되고 새로운 각질세포가 그 기능을 대신하게 되는데, 이러한 반복적인 일련의 변화 과정을 표피 세포의 분화 또는 각화(keratinization)라고 부른다. 또한, 각화과정 중에 각질형성세포는 천연보습인자(Natural moisturizing factor; NMF) 와 세포간 지방질(세라마이드, 콜레스테롤, 지방산)을 생성하면서 각질층을 형성하여 각질층이 견고함과 유연성을 가지게 하여 피부 장벽(skin barrier)으로서의 기능을 보유하게 한다. The stratum corneum (horney layer), which is the outermost layer of the epidermis, is formed from keratinocytes, and consists of keratinocytes that have completed differentiation and a lipid layer surrounding them (Marcelo CL et al, J. Invest. Dermatol., 80, pp37-44, 1983). Keratinocytes are characteristic cells in which basal cells, which continuously proliferate in the lower layer of the epidermis, undergo morphological and functional changes in stages, and rise to the skin surface. After a certain period of time, old keratinocytes are removed from the skin. It is eliminated and new keratinocytes take over their functions. This repetitive series of changes is called differentiation or keratinization of epidermal cells. In addition, during the keratinization process, keratinocytes form a stratum corneum while generating natural moisturizing factor (NMF) and intercellular lipids (ceramide, cholesterol, fatty acids), thereby making the stratum corneum firm and flexible, thereby forming a skin barrier (skin barrier). function as a barrier).
이러한 각질층은 과도한 세안이나, 목욕 등의 생활 습관적 요소나, 건조한 대기 오염 물질 등의 환경적인 요인, 그리고 아토피성 피부나 노인성 피부 같은 내인성 질환 등으로 인해 쉽게 그 기능이 손실될 수 있으며, 실제로 현대에 들어서 더욱 늘어난 다양한 요인들로 인해 최근에는 건조피부증상 및 이로 인한 제반 장해를 호소하는 부분들이 점점 증가하고 있는 추세이다. 또한, 외부 환경 변화, 노화가 진행되면서 피부 내 여러 가지 변화가 발생하면서 피부 장벽 손상을 입게 되고 이에 따라 피부 염증, 건조증, 가려움증 등이 발생할 수 있다.The stratum corneum can easily lose its function due to lifestyle factors such as excessive washing or bathing, environmental factors such as dry air pollutants, and intrinsic diseases such as atopic skin or senile skin. Due to various factors that have increased in recent years, the number of people complaining of dry skin symptoms and various disorders due to them is increasing. In addition, as the external environment changes and aging progresses, various changes in the skin occur and the skin barrier is damaged, which may cause skin inflammation, dryness, itching, and the like.
따라서 피부 장벽을 개선해 줌으로써 피부에 발생하는 다양한 트러블들을 개선해 줄 수 있으며, 최근 들어 이에 대한 연구가 활발히 진행되고 있지만 피부 장벽을 개선해 주는 원료들은 현재까지 많이 보고되어 있지 않다.Therefore, by improving the skin barrier, various troubles occurring on the skin can be improved, and although research on this has been actively conducted recently, raw materials for improving the skin barrier have not been reported so far.
한편, p21 및 p16은 암 억제 단백질로 각각 사이클린 의존성 키나아제 1A(Cyclin-Dependent Kinase Inhibitor 1A, CDKN1A) 및 사이클린 의존성 키나아제 2A(Cyclin-Dependent Kinase Inhibitor 2A, CDKN2A) 유전자로 암호화되어 있다. 다세포 생물의 세포 주기에서 세포분열 및 성장의 반대 신호로 작용하며 다양한 내외부적 요인에 의한 세포분열의 억제 및 노화와 밀접한 관련이 있다.On the other hand, p21 and p16 are cancer suppressor proteins, respectively, cyclin-dependent kinase 1A (Cyclin-Dependent Kinase Inhibitor 1A, CDKN1A) and cyclin-dependent kinase 2A (Cyclin-Dependent Kinase Inhibitor 2A, CDKN2A) are encoded by genes. In the cell cycle of multicellular organisms, it acts as the opposite signal of cell division and growth, and is closely related to the inhibition of cell division and aging by various internal and external factors.
또한, 트랜스글루타미나아제 5(transglutaminase 5, TGM5)는 표피의 가시층, 과립층, 기저층에서 주로 발현되며 표피의 분화(Differentiation)에 관여하는 피부장벽 구성의 핵심 유전자이다. 칼슘에 의해서 즉각적으로 발현이 증가하며, 이후 피부세포의 분화 정도에 따라 다시 발현이 감소하는 특성을 가진다. 피부장벽의 주요 구성 단백질인 involucrin, loricrin, SPR1, SPR2를 기질로 가지며, 글루타민(Glutamine)과 라이신(Lysine)을 연결하는 역할을 수행함. 따라서 표피의 구조를 형성하며, 피부장벽과 밀접한 연관이 있다. In addition, transglutaminase 5 (TGM5) is mainly expressed in the visible, granular, and basal layers of the epidermis and is a key gene in the construction of the skin barrier involved in the differentiation of the epidermis. The expression increases immediately by calcium, and then the expression decreases again according to the degree of differentiation of skin cells. It has involucrin, loricrin, SPR1, and SPR2, the main constituent proteins of the skin barrier, as substrates, and plays a role in linking glutamine and lysine. Therefore, it forms the structure of the epidermis and is closely related to the skin barrier.
엔보플라킨(envoplakin, EVPL)은 표피세포 transglutaminase의 기질로 작용하며, 각질세포의 분화과정에서 높은 수준의 발현을 보인다. 각질층의 구성에서 주요한 구조적인 역할을 수행하며, periplakin과 협동하여 피부장벽을 구성한다. 주로 접착반(Desmosome)에 발현되며, 각질세포의 결합에 관여하는 것으로 알려져있다. Envoplakin (EVPL) acts as a substrate for epidermal transglutaminase, and shows a high level of expression in the differentiation process of keratinocytes. It plays a major structural role in the composition of the stratum corneum and forms the skin barrier in cooperation with periplakin. It is mainly expressed in desmosomes and is known to be involved in the binding of keratinocytes.
이에 본 발명자들은, 피부장벽 개선 효과를 나타낼 수 있는 천연 원료를 개발하기 위하여 연구한 결과, 바질 오일이 각질세포의 노화관련 유전자 발현을 억제하고, 피부장벽 관련 유전자 발현을 증가시키는 효과가 있음을 확인하여 본 발명을 완성하였다.Accordingly, the present inventors studied to develop a natural raw material that can improve the skin barrier, and as a result, it was confirmed that basil oil has the effect of suppressing the expression of aging-related genes in keratinocytes and increasing the expression of genes related to the skin barrier. Thus, the present invention was completed.
본 발명의 목적은 바질 오일을 포함하는 피부장벽 강화용 화장료 조성물을 제공하는 것이다.An object of the present invention is to provide a cosmetic composition for strengthening the skin barrier comprising basil oil.
본 발명의 다른 목적은 바질 오일을 포함하는 피부 각질형성세포 분화 유도용 화장료 조성물을 제공하는 것이다.Another object of the present invention is to provide a cosmetic composition for inducing differentiation of skin keratinocytes comprising basil oil.
본 발명의 다른 목적은 바질 오일을 포함하는 피부 주름 개선용 화장료 조성물을 제공하는 것이다.Another object of the present invention is to provide a cosmetic composition for improving skin wrinkles comprising basil oil.
본 발명의 또 다른 목적은 바질 오일을 포함하는 피부장벽 강화용 건강기능식품 조성물을 제공하는 것이다.Another object of the present invention is to provide a health functional food composition for strengthening the skin barrier comprising basil oil.
본 발명의 다른 목적은 바질 오일을 포함하는 피부 각질형성세포 분화 유도용 건강기능식품 조성물을 제공하는 것이다.Another object of the present invention is to provide a health functional food composition for inducing differentiation of skin keratinocytes comprising basil oil.
본 발명의 다른 목적은 바질 오일을 포함하는 피부 주름 개선용 건강기능식품 조성물을 제공하는 것이다.Another object of the present invention is to provide a health functional food composition for improving skin wrinkles comprising basil oil.
상기 목적을 달성하기 위하여,In order to achieve the above object,
본 발명은 바질 오일을 포함하는 피부장벽 강화용 화장료 조성물을 제공한다.The present invention provides a cosmetic composition for strengthening the skin barrier comprising basil oil.
또한, 본 발명은 바질 오일을 포함하는 피부 각질형성세포 분화 유도용 화장료 조성물을 제공한다.In addition, the present invention provides a cosmetic composition for inducing differentiation of skin keratinocytes comprising basil oil.
나아가, 본 발명은 바질 오일을 포함하는 피부 주름 개선용 화장료 조성물을 제공한다.Furthermore, the present invention provides a cosmetic composition for improving skin wrinkles comprising basil oil.
또한, 본 발명은 바질 오일을 포함하는 피부장벽 강화용 건강기능식품 조성물을 제공한다.In addition, the present invention provides a health functional food composition for strengthening the skin barrier comprising basil oil.
나아가, 본 발명은 바질 오일을 포함하는 피부 각질형성세포 분화 유도용 건강기능식품 조성물을 제공한다.Furthermore, the present invention provides a health functional food composition for inducing differentiation of skin keratinocytes comprising basil oil.
더 나아가, 본 발명은 바질 오일을 포함하는 피부 주름 개선용 건강기능식품 조성물을 제공한다.Furthermore, the present invention provides a health functional food composition for improving skin wrinkles comprising basil oil.
본 발명에 따른 바질 오일은 각질형성세포에 처리시 피부장벽 관련 유전자의 발현을 증가시키고, 피부 노화 관련 유전자의 발현을 억제시킴을 확인함에 따라, 피부장벽 기능을 강화하고 피부 노화를 방지함으로써, 나아가 피부장벽 손상에 의한 피부 건조 또는 피부 염증을 방지하고 주름을 개선시키는 효과가 있어, 화장품 및 식품 분야에서 유용하게 사용될 수 있다.Basil oil according to the present invention increases the expression of skin barrier-related genes and inhibits the expression of skin aging-related genes when treated with keratinocytes, thereby strengthening the skin barrier function and preventing skin aging, further It has an effect of preventing skin dryness or skin inflammation caused by damage to the skin barrier and improving wrinkles, and thus can be usefully used in cosmetics and food fields.
도 1은 바질 오일 처리 농도 및 처리 시간에 따른 HaCaT 세포에서의 세포독성을 측정한 결과이다.
도 2는 바질 오일 처리에 따른 피부 노화 관련 유전자 CDKN1A 및 CDKN2A의 발현량을 확인한 결과이다.
도 3은 바질 오일 처리에 따른 피부 장벽 관련 유전자 TGM5(transglutaminase 5) 및 EVPL(Envoplakin)의 발현량을 확인한 결과이다.1 is a result of measuring cytotoxicity in HaCaT cells according to basil oil treatment concentration and treatment time.
2 is a result of confirming the expression levels of skin aging-related genes CDKN1A and CDKN2A according to basil oil treatment.
3 is a result of confirming the expression levels of skin barrier-related genes TGM5 (transglutaminase 5) and EVPL (Envoplakin) according to basil oil treatment.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
화장료 조성물cosmetic composition
본 발명은 바질 오일을 포함하는 피부장벽 강화용, 피부 각질형성세포 분화 유도용 또는 피부 주름 개선용 화장료 조성물을 제공한다.The present invention provides a cosmetic composition for skin barrier strengthening, skin keratinocyte differentiation induction, or skin wrinkle improvement comprising basil oil.
본 발명에 따른 화장료 조성물에 있어서, 상기 바질 오일은 바질(Ocimum canum)의 잎에서 추출된 것일 수 있고, 바람직하게는 Ocimum canum의 잎을 증류법(Steam distillation)으로 추출하여 수득된 것일 수 있다.In the cosmetic composition according to the present invention, the basil oil may be extracted from the leaves of basil ( Ocimum canum ), preferably obtained by extracting the leaves of Ocimum canum by steam distillation.
본 발명에 따른 화장료 조성물에 있어서, 상기 조성물은 트랜스글루타미나아제(transglutaminase) 및 엔보플라킨(envoplakin) 중 어느 하나 이상의 유전자 발현을 증가시키는 것일 수 있고, 상기 유전자 발현을 증가시킴으로써 피부장벽 기능 강화 효과를 발휘하는 것일 수 있다. 나아가, 피부건조 또는 피부염증유발을 방지하는 것일 수 있다.In the cosmetic composition according to the present invention, the composition may increase the expression of any one or more genes of transglutaminase and envoplakin, and strengthening the skin barrier function by increasing the gene expression it may be effective. Furthermore, it may be to prevent skin dryness or skin inflammation.
본 발명에 따른 화장료 조성물에 있어서, 상기 조성물은 사이클린 의존성 키나아제 유전자 발현을 억제시키는 것일 수 있고, 바람직하게는 사이클린 의존성 키나아제 1A(Cyclin-Dependent Kinase Inhibitor 1A) 및 사이클린 의존성 키나아제 2A(Cyclin-Dependent Kinase Inhibitor 2A) 유전자 중 어느 하나 이상의 유전자 발현을 억제시키는 것일 수 있으며, 상기 유전자 발현을 억제시킴으로써 피부 노화 방지 효과를 발휘하는 것일 수 있다. 나아가, 주름 개선을 억제 또는 개선시키는 것일 수 있다.In the cosmetic composition according to the present invention, the composition may inhibit cyclin-dependent kinase gene expression, preferably cyclin-dependent kinase 1A (Cyclin-Dependent Kinase Inhibitor 1A) and cyclin-dependent kinase 2A (Cyclin-Dependent Kinase Inhibitor) 2A) may be to suppress the expression of any one or more genes among genes, and may be to exert an anti-aging effect on the skin by suppressing the expression of the gene. Furthermore, it may be to suppress or improve wrinkle improvement.
본 발명에 따른 화장료 조성물에 있어서, 상기 화장료 조성물은 상기 바질 오일을 상기 조성물 총 중량에 대하여 0.0001~90 중량부의 양으로 함유할 수 있으나, 바람직한 효과를 제공할 수 있는 유효량을 포함한다면 이에 제한되지 않는다.In the cosmetic composition according to the present invention, the cosmetic composition may contain the basil oil in an amount of 0.0001 to 90 parts by weight based on the total weight of the composition, but if it contains an effective amount capable of providing a desirable effect, it is not limited thereto. .
본 발명에 따른 화장료 조성물은 피부외용연고, 크림, 유연화장수, 영양화장수, 팩, 에센스, 헤어토닉, 샴푸, 린스, 헤어 컨디셔너, 헤어 트리트먼트, 젤, 스킨로션, 스킨소프너, 스킨토너, 아스트린젠트, 로션, 밀크로션, 모이스처 로션, 영양로션, 마사지 크림, 영양크림, 모이스처 크림, 핸드 크림, 파운데이션, 영양에센스, 선스크린, 비누, 클렌징폼, 클렌징로션, 클렌징크림, 바디 로션 및 바디 클렌저로 이루어지는 군으로부터 선택된 제형을 가질 수 있으며, 이에 제한되지 않는다. 이들 각 제형의 조성물은 그 제형의 제제화에 필요하고 적절한 각종의 기제와 첨가물을 함유할 수 있으며, 이들 성분의 종류와 양은 당업자에 의해 용이하게 선정될 수 있다.The cosmetic composition according to the present invention is an external skin ointment, cream, softening lotion, nourishing lotion, pack, essence, hair tonic, shampoo, conditioner, hair conditioner, hair treatment, gel, skin lotion, skin softener, skin toner, astringent, Group consisting of lotion, milk lotion, moisture lotion, nourishing lotion, massage cream, nourishing cream, moisture cream, hand cream, foundation, nourishing essence, sunscreen, soap, cleansing foam, cleansing lotion, cleansing cream, body lotion and body cleanser It may have a formulation selected from, but is not limited thereto. The composition of each of these formulations may contain various bases and additives necessary and appropriate for the formulation of the formulation, and the types and amounts of these components can be easily selected by those skilled in the art.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물섬유, 식물섬유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, animal fiber, vegetable fiber, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as a carrier component. can
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In particular, in the case of a spray, additional chlorofluorohydrocarbon, propane /may contain propellants such as butane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액의 경우에는 담체 성분으로서 용매, 용매화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or emulsion, a solvent, solvating agent or emulsifying agent is used as a carrier component, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butylglycol oil, glycerol fatty esters, fatty acid esters of polyethylene glycol or sorbitan.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, as a carrier component, water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters, microcrystalline Cellulose, aluminum metahydroxide, bentonite, agar or tracanth may be used.
본 발명의 제형이 계면-활성제 함유 클렌징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 리놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is a surfactant-containing cleansing agent, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide as carrier components Ether sulfate, alkylamidobetaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, linolin derivative or ethoxylated glycerol fatty acid ester and the like can be used.
본 발명의 제형은 형광물질, 살진균제, 굴수성 유발물질, 보습체, 방향제, 방향제 담체, 단백질, 용해화제, 당유도체, 일광차단제, 비타민, 식물 추출물 등을 포함하는 부형제를 추가로 함유할 수 있다.The formulation of the present invention may further contain excipients including fluorescent substances, fungicides, hydrophobicity inducers, moisturizing agents, fragrances, fragrance carriers, proteins, solubilizers, sugar derivatives, sunscreens, vitamins, plant extracts, and the like. .
상기와 같이 화장료 조성물을 의약품 또는 화장품으로 제형화할 경우, 활성 성분에 대한 담체로 작용하는 피부에 적용가능한 공지의 부형제를 포함할 수 있다. 의약품으로의 제형화시에는 [Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA]에 개시되어 있는 내용을 참조할 수 있으며, 화장품으로 제형화시에는 [International cosmetic ingredient dictionary, 6th ed., The cosmetic, Toiletry and Fragrance Association, Inc., Washington, 1995]에 개시되어 있는 내용을 참조할 수 있을 것이다. 상기 문헌들은 본 명세서의 일부로서 포함된다.When the cosmetic composition is formulated as a pharmaceutical or cosmetic as described above, it may contain a known excipient applicable to the skin acting as a carrier for the active ingredient. When formulating into pharmaceuticals, reference may be made to the contents disclosed in [Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA], and when formulating into cosmetics, [International cosmetic ingredient dictionary, 6th ed., The cosmetic, Toiletry] and Fragrance Association, Inc., Washington, 1995]. These documents are incorporated as part of this specification.
건강식품 또는 건강기능식품 조성물Health food or health functional food composition
본 발명은 바질 오일을 포함하는 피부장벽 강화용, 피부 각질형성세포 분화 유도용 또는 피부 주름 개선용 건강식품 또는 건강기능 조성물을 제공한다.The present invention provides a health food or health functional composition for skin barrier strengthening, skin keratinocyte differentiation induction, or skin wrinkle improvement containing basil oil.
본 발명의 바질 오일을 건강기능식품 및 건강식품 조성물로 사용하는 경우, 식품의 종류에는 특별한 제한은 없다. 본 발명의 바질 오일을 첨가할 수 있는 식품의 예로는 드링크제, 육류, 소시지, 빵, 비스킷, 떡, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 알코올 음료 및 비타민 복합제, 유제품 및 유가공 제품 등이 있으며, 통상적인 의미에서의 건강기능식품 및 건강식품 조성물을 모두 포함한다.When the basil oil of the present invention is used as a health functional food and health food composition, there is no particular limitation on the type of food. Examples of foods to which the basil oil of the present invention can be added include drinks, meat, sausages, bread, biscuits, rice cakes, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, There are various soups, beverages, alcoholic beverages and vitamin complexes, dairy products, and dairy products, and includes all health functional foods and health food compositions in the ordinary sense.
본 발명에 따른 바질 오일을 함유하는 건강기능식품 및 건강식품 조성물은 식품에 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 바질 오일의 혼합량은 그의 사용 목적(예방 또는 개선용)에 따라 적합하게 결정될 수 있다. 일반적으로, 건강기능식품 및 건강식품 조성물 중의 상기 조성물의 양은 전체 식품 중량의 0.1 내지 90 중량부로 가할 수 있다. 그러나 건강 유지를 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 바질 오일은 상기 범위 이상의 양으로도 사용될 수 있다.The health functional food and health food composition containing basil oil according to the present invention may be added to food as it is or used together with other food or food ingredients, and may be appropriately used according to a conventional method. The mixing amount of basil oil may be appropriately determined depending on the purpose of its use (for prevention or improvement). In general, the amount of the composition in the health functional food and health food composition may be added in an amount of 0.1 to 90 parts by weight based on the total weight of the food. However, in the case of long-term intake for health maintenance or health control, the above amount may be less than the above range, and since there is no problem in terms of safety, basil oil may be used in an amount above the above range.
본 발명의 건강기능식품 및 건강식품 조성물은 지시된 비율로 필수 성분으로서 본 발명 바질 오일을 함유하는 외에는 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트라이톨 등의 당알코올이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 건강기능식품 및 건강식품 조성물 100 당 일반적으로 약 1 내지 20 g, 바람직하게는 약 5 내지 12 g이다.The health functional food and health food composition of the present invention is not particularly limited in other ingredients except for containing the basil oil of the present invention as an essential ingredient in the indicated ratio, and various flavoring agents or natural carbohydrates are added as additional ingredients like conventional beverages. may contain. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; disaccharides such as maltose, sucrose and the like; and polysaccharides such as conventional sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those described above, natural flavoring agents (taumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 health functional food and health food composition of the present invention.
상기 외에 본 발명의 바질 오일을 함유하는 건강기능식품 및 건강식품 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 본 발명의 건강기능식품 및 건강식품 조성물은 천연 과일쥬스 및 과일쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다.In addition to the above, the health functional food and health food composition containing basil oil of the present invention are various nutrients, vitamins, minerals (electrolytes), synthetic flavoring agents and flavoring agents such as natural flavoring agents, coloring agents and thickening agents (cheese, chocolate, etc.) ), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. In addition, the health functional food and health food composition of the present invention may contain natural fruit juice, fruit juice, and fruit for the production of fruit juice drinks and vegetable drinks.
이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 바질 오일을 함유하는 건강기능식품 및 건강식품 조성물 100 중량부 당 0.1 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.These components may be used independently or in combination. The proportion of these additives is not so important, but is generally selected in the range of 0.1 to about 20 parts by weight per 100 parts by weight of the health functional food and health food composition containing the basil oil of the present invention.
이하, 본 발명을 하기의 실시예에 의하여 더욱 상세하게 설명한다. 단, 하기의 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기의 실시예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the following examples are merely illustrative of the present invention, and the content of the present invention is not limited by the following examples.
<실험예 1> 바질 오일의 세포독성 측정<Experimental Example 1> Measurement of cytotoxicity of basil oil
바질 오일(bail oil)은 ㈜콘스텔라(경기도 군포시)에서 100%원액을 구매하여 사용하였다. 인간 피부세포/각질세포주의 일종인 HaCaT세포는 DMEM (Dulbecco′Modified Eagle′), 10% FBS (Fetal Bovine Serum), 1% Penicillin/Streptomycin을 배합한 배지에 의해 배양되었으며, 5% CO2를 지속적으로 공급하는 37℃ 배양기 내에서 유지되었다. 해당 세포는 96-well plate 위에서 배양되었으며, 90% 이상 성장하였을 때 (90% of Visual Confluency)에 상기 바질 오일을 0.001, 0.01 및 0.05%의 농도로 72시간 동안 처리하였다. 이 후 배양액을 제거한 후, 96-well plate 상의 세포를 PBS (Phosphate-buffered saline)로 3회 세척하였다. 다음으로 CCK-8 용액 (CK04, Dojindo Molecular Technologies, USA)을 10μL 추가한 후에 4시간 동안 37℃에서 반응 시켰다. 이후 OD=450nm에서의 흡광도를 측정하여 세포의 생존율을 확인하였다.Basil oil was used after purchasing a 100% undiluted solution from Constella Co., Ltd. (Gunpo-si, Gyeonggi-do). HaCaT cells, a kind of human skin cell/keratinocyte line, were cultured in a medium containing DMEM (Dulbecco′Modified Eagle′), 10% FBS (Fetal Bovine Serum), and 1% Penicillin/Streptomycin, and continuously exposed to 5% CO 2 . was maintained in a 37°C incubator supplied with The cells were cultured on a 96-well plate, and when they were grown to 90% or more (90% of Visual Confluency), the basil oil was treated at concentrations of 0.001, 0.01 and 0.05% for 72 hours. After removing the culture medium, the cells on the 96-well plate were washed 3 times with PBS (Phosphate-buffered saline). Next, 10 μL of CCK-8 solution (CK04, Dojindo Molecular Technologies, USA) was added and reacted at 37° C. for 4 hours. Thereafter, the absorbance at OD=450 nm was measured to confirm the viability of the cells.
도 1은 바질 오일 처리 농도 및 처리 시간에 따른 HaCaT 세포에서의 세포독성을 측정한 결과이다.1 is a result of measuring cytotoxicity in HaCaT cells according to basil oil treatment concentration and treatment time.
그 결과, 0.01% 이하의 바질 오일 처리가 인간 피부세포의 일종인 각질세포의 생존 및 분열에 거의 영향을 주지 않는 것을 확인하였다.As a result, it was confirmed that treatment with 0.01% or less of basil oil had little effect on the survival and division of keratinocytes, a type of human skin cells.
<실험예 2> 각질세포의 노화에 대한 바질 오일의 영향 확인<Experimental Example 2> Confirmation of the effect of basil oil on the aging of keratinocytes
인간 피부세포/각질세포주의 일종인 HaCaT세포는 DMEM (Dulbecco′Modified Eagle′을 배합한 배지에 의해 배양되었으며, 5% CO2를 지속적으로 공급하는 37℃ 배양기 내에서 유지되었다. 해당 세포는 96-well plate 위에서 배양되었으며, 90% 이상 성장하였을 때 (90% of Visual Confluency)에 바질 오일을 0.01% 농도로 72시간 동안 처리하였다. 이 후 배양액을 제거한 후, plate 상의 세포를 PBS (Phosphate-buffered saline)로 3회 세척하였다. 수집된 세포에서 RNA를 정제한 후 cDNA를 합성하였으며, qPCR을 이용하여 유전자 정량분석을 수행하였다.HaCaT cells, a kind of human skin cell/keratinocyte line, were cultured in a medium containing DMEM (Dulbecco'Modified Eagle') and maintained in a 37°C incubator continuously supplied with 5% CO 2 . The cells were 96- It was cultured on a well plate, and when it had grown to more than 90% (90% of Visual Confluency), basil oil was treated at a concentration of 0.01% for 72 hours After removing the culture medium, the cells on the plate were washed with PBS (Phosphate-buffered saline). ) After purifying RNA from the collected cells, cDNA was synthesized, and gene quantitative analysis was performed using qPCR.
실시간 중합효소연쇄반응(Real-time polymerase chain reaction, real-time PCR, quantitative real time polymerase chain reaction, qPCR)은 중합효소 연쇄 반응을 기반으로 하는 실험방법으로, 목표 DNA분자의 증폭과 양의 측정을 동시에 할 수 있다. DNA샘플에서 하나 또는 그 이상의 특정 서열을 위해, 실시간 중합효소연쇄반응은 검출과 양의 측정을 할 수 있게 하며, 계량은 절대적인 복제 수 또는 상대적인 양을 셀 수 있다.Real-time polymerase chain reaction (real-time PCR, quantitative real time polymerase chain reaction, qPCR) is an experimental method based on polymerase chain reaction, can do it at the same time For one or more specific sequences in a DNA sample, real-time polymerase chaining allows detection and quantification, which can be either absolute copy number or relative quantity.
실험의 진행은 일반적인 중합효소연쇄반응을 따라 진행하였다. 중요한 특징은, 증폭된 DNA가 실시간으로 측정된다는 것으로, 이 점이 마지막에서 DNA가 관측이 되는 기본적인 중합효소연쇄반응과의 차이점이다. 두 가지의 일반적인 방법이 실시간 중합효소연쇄반응에서 사용되었다. 아무 DNA이중나선에 끼어들어갈 수 있는 불특정한 형광염색, 그리고 올리고뉴클레오티드로 이루어진 서열-특이적 DNA탐침- 형광으로 보고자가 라벨되어 있고, 상보적인 DNA목표에 결합한 뒤 검출되었다. 이번에 사용한 기법은 SYBR 시약을 이용한 비특이선 이중나선의 검출법이다.The experiment proceeded according to the general polymerase chain reaction. An important feature is that the amplified DNA is measured in real time, which is different from the basic polymerase chain reaction in which DNA is observed at the end. Two general methods were used in the real-time polymerase chain reaction. A reporter was labeled with a sequence-specific DNA probe-fluorescence composed of oligonucleotides and an unspecified fluorescence stain capable of intercalating any DNA double helix, and was detected after binding to a complementary DNA target. The technique used this time is the detection of non-specific double helix using SYBR reagent.
도 2는 바질 오일 처리에 따른 피부 노화 관련 유전자 CDKN1A 및 CDKN2A의 발현량을 확인한 결과이다.2 is a result of confirming the expression levels of skin aging-related genes CDKN1A and CDKN2A according to basil oil treatment.
인간 피부세포/각질세포주의 일종인 HaCaT세포에 0.01%의 바질 오일을 처리한 결과, 도 2에 나타난 바와 같이 CDKN1A와 CDKN2A 유전자 발현이 감소됨을 확인하였다. CDKN1A와 CDKN2A 유전자는 다양한 경로를 통해 인간세포의 노화를 촉진하는 p21, p16 단백질을 암호화하고 있다. 따라서 해당 유전자의 발현 감소는 피부의 노화 정도가 감소하였다는 것을 의미한다. 결과적으로, 바질 오일이 인간 각질세포의 노화 억제에 도움을 줄 수 있는 항노화 기능 소재로 유용함을 확인하였다.As a result of treatment with 0.01% basil oil on HaCaT cells, a kind of human skin cell/keratinocyte line, it was confirmed that CDKN1A and CDKN2A gene expression was decreased as shown in FIG. 2 . The CDKN1A and CDKN2A genes encode p21 and p16 proteins that promote aging of human cells through various pathways. Therefore, the decrease in the expression of the gene means that the degree of skin aging is reduced. As a result, it was confirmed that basil oil is useful as an anti-aging material that can help inhibit the aging of human keratinocytes.
<실험예 3> 피부장벽 기능에 대한 바질 오일의 영향 확인<Experimental Example 3> Confirmation of the effect of basil oil on the skin barrier function
인간 피부세포/각질세포주의 일종인 HaCaT세포는 DMEM (Dulbecco′Modified Eagle′e Serum), 1% Penicillin/Streptomycin을 배합한 배지에 의해 배양되었으며, 5% CO2를 지속적으로 공급하는 37℃ 배양기 내에서 유지되었다. 해당 세포는 96-well plate 위에서 배양되었으며, 90% 이상 성장하였을 때 (90% of Visual Confluency)에 바질 오일을 0.01% 농도로 72시간 동안 처리하였다. 이 후 배양액을 제거한 후, plate 상의 세포를 PBS (Phosphate-buffered saline)로 3회 세척하였다. 수집된 세포에서 RNA를 정제한 후 cDNA를 합성하였으며, 실시간 중합효소연쇄반응(qPCR)을 이용하여 유전자 정량분석을 수행하였다. 실험예 2와 마찬가지로, 실험의 진행은 일반적인 중합효소연쇄반응을 따라 진행하였다.HaCaT cells, a kind of human skin cell/keratinocyte line, were cultured in a medium mixed with DMEM (Dulbecco′Modified Eagle′e Serum) and 1% Penicillin/Streptomycin, in a 37°C incubator continuously supplied with 5% CO 2 . was maintained in The cells were cultured on a 96-well plate, and when they were more than 90% grown (90% of Visual Confluency), basil oil was treated at a concentration of 0.01% for 72 hours. After removing the culture medium, the cells on the plate were washed 3 times with PBS (Phosphate-buffered saline). After purifying RNA from the collected cells, cDNA was synthesized, and gene quantitative analysis was performed using real-time polymerase chain reaction (qPCR). As in Experimental Example 2, the experiment proceeded according to a general polymerase chain reaction.
도 3은 바질 오일 처리에 따른 피부 장벽 관련 유전자 TGM5(transglutaminase 5) 및 EVPL(Envoplakin)의 발현량을 확인한 결과이다.3 is a result confirming the expression levels of skin barrier-related genes TGM5 (transglutaminase 5) and EVPL (Envoplakin) according to basil oil treatment.
인간 피부세포/각질세포주의 일종인 HaCaT세포에 0.01%의 바질 오일을 처리한 결과, 도 3에 나타난 바와 같이, TGM5 및 EVPL 유전자 발현이 증가됨을 확인하였다. TGM5 유전자의 발현을 통해 표피에 존재하는 다양한 구조 단백질의 결합을 촉진하고, EVPL 유전자 발현 증가를 통해 피부장벽의 강화에 영향을 미칠 수 있다. 결과적으로, 바질 오일이 인간 각질세포의 분화촉진에 도움을 줄 수 있음을 확인하였다.As a result of treatment with 0.01% basil oil in HaCaT cells, a type of human skin cell/keratinocyte line, it was confirmed that TGM5 and EVPL gene expression was increased as shown in FIG. 3 . It can promote the binding of various structural proteins present in the epidermis through the expression of the TGM5 gene, and influence the strengthening of the skin barrier by increasing the expression of the EVPL gene. As a result, it was confirmed that basil oil can help promote the differentiation of human keratinocytes.
이제까지 본 발명에 대하여 그 바람직한 실시예들을 중심으로 살펴보았다. 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자는 본 발명이 본 발명의 본질적인 특성에서 벗어나지 않는 범위에서 변형된 형태로 구현될 수 있음을 이해할 수 있을 것이다. 그러므로 개시된 실시예들은 한정적인 관점이 아니라 설명적인 관점에서 고려되어야 한다. 본 발명의 범위는 전술한 설명이 아니라 청구범위에 나타나 있으며, 그와 동등한 범위내에 있는 모든 차이점은 본 발명에 포함된 것으로 해석되어야 할 것이다.So far, with respect to the present invention, the preferred embodiments have been looked at. Those of ordinary skill in the art to which the present invention pertains will understand that the present invention can be implemented in a modified form without departing from the essential characteristics of the present invention. Therefore, the disclosed embodiments are to be considered in an illustrative rather than a restrictive sense. The scope of the present invention is indicated in the claims rather than in the foregoing description, and all differences within the scope equivalent thereto should be construed as being included in the present invention.
Claims (10)
상기 바질 오일은 정향나무(Eugenia caryophyllata)의 잎에서 추출된 것을 특징으로 하는 조성물.According to claim 1,
The basil oil is a composition, characterized in that extracted from the leaves of the clove tree ( Eugenia caryophyllata ).
상기 조성물은 트랜스글루타미나아제(transglutaminase) 및 엔보플라킨(envoplakin) 중 어느 하나 이상의 유전자 발현을 증가시키는 것을 특징으로 하는 조성물.According to claim 1,
The composition is a composition characterized in that it increases the expression of any one or more of transglutaminase (transglutaminase) and envoplakin (envoplakin).
상기 조성물은 피부건조 또는 피부염증유발을 방지하는 것을 특징으로 하는 조성물.The method of claim 1,
The composition is a composition characterized in that it prevents skin dryness or skin inflammation.
상기 조성물은 피부외용연고, 크림, 유연화장수, 영양화장수, 팩, 에센스, 헤어토닉, 샴푸, 린스, 헤어 컨디셔너, 헤어 트리트먼트, 젤, 스킨로션, 스킨소프너, 스킨토너, 아스트린젠트, 로션, 밀크 로션, 모이스처 로션, 영양로션, 마사지 크림, 영양크림, 모이스처 크림, 핸드 크림, 파운데이션, 영양에센스, 선스크린, 비누, 클렌징폼, 클렌징로션, 클렌징크림, 바디 로션 및 바디 클렌저로 이루어진 그룹에서 선택되는 어느 하나의 제형으로 제조된 것을 특징으로 하는 조성물.The method of claim 1,
The composition is an external skin ointment, cream, softening lotion, nourishing lotion, pack, essence, hair tonic, shampoo, conditioner, hair conditioner, hair treatment, gel, skin lotion, skin softener, skin toner, astringent, lotion, milk lotion , moisture lotion, nourishing lotion, massage cream, nourishing cream, moisture cream, hand cream, foundation, nourishing essence, sunscreen, soap, cleansing foam, cleansing lotion, cleansing cream, body lotion and body cleanser A composition, characterized in that it is prepared in one dosage form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190157149A KR102392334B1 (en) | 2019-11-29 | 2019-11-29 | Cosmetic composition for enhancing skin barrier comprising basil oil |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190157149A KR102392334B1 (en) | 2019-11-29 | 2019-11-29 | Cosmetic composition for enhancing skin barrier comprising basil oil |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210067483A true KR20210067483A (en) | 2021-06-08 |
| KR102392334B1 KR102392334B1 (en) | 2022-05-02 |
Family
ID=76399803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020190157149A KR102392334B1 (en) | 2019-11-29 | 2019-11-29 | Cosmetic composition for enhancing skin barrier comprising basil oil |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102392334B1 (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04154898A (en) * | 1990-10-19 | 1992-05-27 | Kao Corp | Modified basil essential oil and its production |
| KR20100044576A (en) * | 2008-10-22 | 2010-04-30 | 이병수 | Cosmetic composition for prevented dermatitis and cosmetic using thereof |
| KR20170000430A (en) | 2015-06-23 | 2017-01-03 | 한경대학교 산학협력단 | Noodle using the dextrin particle surrounded with liquid phase oil on room temperature to reduce the cooking time |
| KR20180014356A (en) * | 2016-07-29 | 2018-02-08 | 코스맥스 주식회사 | Composition for alleviating skin irritation and skin inflammation induced by particulate matter comprising extracts mixture of Ocimum sanctum, Mentha haplocalyx, and Azadirachta indica |
| KR20180037455A (en) * | 2016-10-04 | 2018-04-12 | (주) 앤디 | Composition comprising natural herbs essential having antibiotic activity and process thereof |
| KR20190037036A (en) * | 2017-09-28 | 2019-04-05 | 주식회사 세바바이오텍 | Cosmetic composition for enhancing function of skin barrier and anti wrinkle comprising agastache rugosa leaf extract |
| KR20190099905A (en) * | 2018-02-20 | 2019-08-28 | 대구한의대학교산학협력단 | A cosmetic composition for sunprotection using a chamomile essential oil |
-
2019
- 2019-11-29 KR KR1020190157149A patent/KR102392334B1/en active IP Right Grant
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04154898A (en) * | 1990-10-19 | 1992-05-27 | Kao Corp | Modified basil essential oil and its production |
| KR20100044576A (en) * | 2008-10-22 | 2010-04-30 | 이병수 | Cosmetic composition for prevented dermatitis and cosmetic using thereof |
| KR20170000430A (en) | 2015-06-23 | 2017-01-03 | 한경대학교 산학협력단 | Noodle using the dextrin particle surrounded with liquid phase oil on room temperature to reduce the cooking time |
| KR20180014356A (en) * | 2016-07-29 | 2018-02-08 | 코스맥스 주식회사 | Composition for alleviating skin irritation and skin inflammation induced by particulate matter comprising extracts mixture of Ocimum sanctum, Mentha haplocalyx, and Azadirachta indica |
| KR20180037455A (en) * | 2016-10-04 | 2018-04-12 | (주) 앤디 | Composition comprising natural herbs essential having antibiotic activity and process thereof |
| KR20190037036A (en) * | 2017-09-28 | 2019-04-05 | 주식회사 세바바이오텍 | Cosmetic composition for enhancing function of skin barrier and anti wrinkle comprising agastache rugosa leaf extract |
| KR20190099905A (en) * | 2018-02-20 | 2019-08-28 | 대구한의대학교산학협력단 | A cosmetic composition for sunprotection using a chamomile essential oil |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102392334B1 (en) | 2022-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102126469B1 (en) | Cosmetic Compositions comprising extract of Dendrobium candidum flower extract | |
| KR101819727B1 (en) | Composition containing ginseng berry extract using processing of herbal medicine | |
| KR101440469B1 (en) | Method of fermented wild ginseng root using complex strains and cosmetic composition comprising thereof | |
| KR102126470B1 (en) | Cosmetic Composition for comprising longanae arillus extracts | |
| KR102536371B1 (en) | Composition Comprising Lactobacillus rhamnosus, Culture Fluid, or Culture Fluid Extract thereof with Anti-Inflammatory, Moisturizing, Skin Barrier, and Skin Cell Regeneration Property as Active Ingredient | |
| KR101634668B1 (en) | Cosmetic composition comprising fermented extract of mistletoe for anti-oxidation or whitening | |
| CN111201012A (en) | Cosmetic composition for skin whitening and wrinkle improvement comprising centella asiatica adventitious root extract as active ingredient | |
| JPWO2018123828A1 (en) | Fermented product and method for producing the same | |
| KR102236071B1 (en) | Composition for Improving Skin Trouble Using an Extract of Centella asiatica or Paeonia lactiflora Cultured with Magma Seawater | |
| JP2023171950A (en) | Anti-aging agent, antioxidant, anti-inflammatory agent, and whitening agent, as well as cosmetic | |
| KR102122649B1 (en) | Cosmetic composition comprising lactic acid and gluconolactone for enhancing skin barrier | |
| KR102053994B1 (en) | Cosmetic composition for skin whitening and moisturizing comprising larva extract of Protaetia brevitarsis as effective component | |
| KR102392334B1 (en) | Cosmetic composition for enhancing skin barrier comprising basil oil | |
| KR101863895B1 (en) | Composition for skin whitening comprising Stachys sieboldii extract fermented using Hericium erinaceum mycelium as effective component | |
| KR102478737B1 (en) | Cosmetic composition for enhancing skin barrier comprising clove oil | |
| KR101050484B1 (en) | Skin whitening composition containing lactone compound as an active ingredient | |
| KR102526287B1 (en) | Composition for anti-inflammation and anti-wrinkle comprising fermentative product of Gryllus bimaculatus extract as effective component | |
| KR102173406B1 (en) | Composition for Improving Skin Conditions with Exfoliation, Moisturizing, and Skin Soothing Property Comprising Complex Extract of Mangifera indica as Active Ingredient | |
| JP4136207B2 (en) | Cosmetics, quasi drugs, pharmaceuticals, food | |
| KR102331119B1 (en) | Composition for preventing skin anti-aging comprising fermented black rice extract and fermented peanut sprout extract | |
| KR102264157B1 (en) | Cosmetic composition for improving skin whitening and cleansing comprising fermented liquor of sheath of bamboo shoot as effective component | |
| KR20220141191A (en) | Composition for Skin Whitening, Moisturizing, Strengthening Skin Barrier, Skin Cell Regeneration, and Anti-Wrinkle Property Comprising Fermented Extract of Broussonetia kazinoki as Active Ingredient | |
| KR101924446B1 (en) | Composition containing ginseng berry extract using processing of herbal medicine | |
| JP2011051920A (en) | Bleaching agent | |
| KR102573041B1 (en) | Composition for skin moisturizing comprising Capsosiphon fulvescens extract as effective component |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |